[SCHEDULE 13G/A] Alto Neuroscience Inc. SEC Filing
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 1,624,000 shares of Alto Neuroscience (ANRO), representing 6.0% of the outstanding common stock based on 27,072,129 shares outstanding. Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd., and Mr. Boyd, as managing member, report shared voting and shared dispositive power over these shares and no sole voting or dispositive power. The filing states the shares are held in the ordinary course of business and not for the purpose of influencing control. The Master Fund is identified as the direct holder and retains the right to proceeds or dividends from the securities.
Armistice Capital, LLC e Steven Boyd dichiarano la propriet脿 effettiva di 1.624.000 azioni di Alto Neuroscience (ANRO), pari al 6,0% del capitale sociale in circolazione su un totale di 27.072.129 azioni. Armistice Capital, in qualit脿 di gestore degli investimenti per Armistice Capital Master Fund Ltd., e il sig. Boyd, in qualit脿 di membro direttivo, comunicano di detenere la potest脿 di voto condivisa e la facolt脿 dispositiva condivisa su tali azioni e di non avere alcuna potest脿 di voto o facolt脿 dispositiva esclusiva. La comunicazione specifica che le azioni sono detenute nell'ambito ordinario dell'attivit脿 commerciale e non con l'intento di esercitare controllo. Il Master Fund 猫 indicato come detentore diretto e mantiene il diritto ai proventi o ai dividendi derivanti dai titoli.
Armistice Capital, LLC y Steven Boyd informan la propiedad beneficiosa de 1.624.000 acciones de Alto Neuroscience (ANRO), que representan el 6,0% del capital social en circulaci贸n, sobre un total de 27.072.129 acciones en circulaci贸n. Armistice Capital, como gestor de inversiones de Armistice Capital Master Fund Ltd., y el Sr. Boyd, como miembro gerente, notifican que poseen poder de voto compartido y poder dispositvo compartido sobre estas acciones y que no tienen poder de voto ni poder dispositvo exclusivo. La presentaci贸n indica que las acciones se mantienen en el curso ordinario del negocio y no con la finalidad de influir en el control. El Master Fund se identifica como el titular directo y conserva el derecho a los ingresos o dividendos de los valores.
Armistice Capital, LLC鞕� 鞀ろ嫲敫� 氤挫澊電� Alto Neuroscience(ANRO)鞚� 氤错喌欤� 1,624,000欤茧ゼ 鞁れ唽鞙犿晿瓿� 鞛堨溂氅�, 鞚措姅 鞝勳泊 鞙犿喌欤检嫕 27,072,129欤� 旮办鞙茧 6.0%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頃╇媹雼�. Armistice Capital鞚� Armistice Capital Master Fund Ltd.鞚� 韴瀽鞖挫毄靷靹�, 氤挫澊電� 甏�毽� 氅る矂搿滌劀 頃措嫻 欤检嫕鞐� 雽�頃� 瓿惦彊 鞚橁舶甓岅臣 瓿惦彊 觳橂秳甓�鞚� 氤挫湢頃橂┌ 雼弲 鞚橁舶甓岇澊雮� 雼弲 觳橂秳甓岇潃 鞐�雼り碃 氤搓碃頃╇媹雼�. 鞝滌稖靹滌棎電� 鞚� 欤检嫕霌れ澊 靷梾鞚� 韱奠儊鞝侅澑 氩旍渼 雮挫棎靹� 氤挫湢霅橁碃 鞛堨溂氅� 歆�氚瓣秾 頄夓偓 氇╈爜鞚� 鞎勲媹霛缄碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. Master Fund臧� 歆侅爲 氤挫湢鞛愲 旮办灛霅橃柎 鞛堨溂氅�, 歃濌秾鞙茧攵�韯� 氚滌儩頃橂姅 靾橃澋 霕愲姅 氚半嫻旮堨潉 氚涭潉 甓岆Μ毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟.
Armistice Capital, LLC et Steven Boyd d茅clarent la propri茅t茅 b茅n茅ficiaire de 1 624 000 actions d'Alto Neuroscience (ANRO), soit 6,0 % des actions ordinaires en circulation sur la base de 27 072 129 actions en circulation. Armistice Capital, en tant que gestionnaire d'investissement d'Armistice Capital Master Fund Ltd., et M. Boyd, en tant que membre g茅rant, d茅clarent disposer d'un pouvoir de vote partag茅 et d'un pouvoir dispositif partag茅 sur ces actions et de aucun pouvoir de vote ni pouvoir dispositif exclusif. Le d茅p么t pr茅cise que les actions sont d茅tenues dans le cours normal des affaires et non dans le but d'influencer le contr么le. Le Master Fund est identifi茅 comme le d茅tenteur direct et conserve le droit aux produits ou dividendes des titres.
Armistice Capital, LLC und Steven Boyd geben den wirtschaftlichen Eigentum an 1.624.000 Aktien von Alto Neuroscience (ANRO) an, was 6,0% des ausstehenden Stammkapitals auf Basis von 27.072.129 ausstehenden Aktien entspricht. Armistice Capital, als Investmentmanager des Armistice Capital Master Fund Ltd., und Herr Boyd, als gesch盲ftsf眉hrendes Mitglied, melden gemeinsames Stimmrecht und gemeinsame Verf眉gungsmacht 眉ber diese Aktien und keine alleinige Stimm- oder Verf眉gungsmacht. In der Meldung hei脽t es, die Aktien w眉rden im normalen Gesch盲ftsverlauf gehalten und nicht mit dem Zweck, die Kontrolle zu beeinflussen. Der Master Fund wird als unmittelbarer Inhaber angegeben und beh盲lt das Recht auf Ertr盲ge oder Dividenden aus den Wertpapieren.
- Material stake disclosed: Reporting persons beneficially own 1,624,000 shares, representing 6.0% of the class.
- Clear reporting structure: Armistice Capital identifies its role as investment manager to the Master Fund and discloses shared voting and dispositive power.
- Passive intent stated: The filing certifies the securities are held in the ordinary course of business and not to influence control.
- None.
Insights
TL;DR: Armistice holds a meaningful passive stake (6.0%) via its Master Fund with shared voting/dispositive power, indicating a notable but non-controlling investor position.
Armistice Capital reports beneficial ownership of 1,624,000 shares (6.0%). The structure 鈥� an investment manager exercising shared voting and dispositive power on behalf of the Master Fund 鈥� is typical for asset managers and signals coordinated reporting rather than a control intent. The certification emphasizes ordinary-course holdings and disclaims an intent to influence control, which is consistent with a Schedule 13G filing as opposed to an activist 13D. For investors, this filing documents a concentrated holder but does not imply governance changes.
TL;DR: A 6.0% passive position with shared power is material for disclosure but does not alone indicate control or activist intentions.
The filing clarifies that Armistice, via an Investment Management Agreement, exercises voting and investment power for the Master Fund, and Mr. Boyd is reported as managing member with shared authority. The explicit statement that holdings are ordinary-course and not for changing control aligns with Schedule 13G treatment. From a governance perspective, the reporting persons could influence outcomes if they coordinate with other large holders, but this filing contains no such indication.
Armistice Capital, LLC e Steven Boyd dichiarano la propriet脿 effettiva di 1.624.000 azioni di Alto Neuroscience (ANRO), pari al 6,0% del capitale sociale in circolazione su un totale di 27.072.129 azioni. Armistice Capital, in qualit脿 di gestore degli investimenti per Armistice Capital Master Fund Ltd., e il sig. Boyd, in qualit脿 di membro direttivo, comunicano di detenere la potest脿 di voto condivisa e la facolt脿 dispositiva condivisa su tali azioni e di non avere alcuna potest脿 di voto o facolt脿 dispositiva esclusiva. La comunicazione specifica che le azioni sono detenute nell'ambito ordinario dell'attivit脿 commerciale e non con l'intento di esercitare controllo. Il Master Fund 猫 indicato come detentore diretto e mantiene il diritto ai proventi o ai dividendi derivanti dai titoli.
Armistice Capital, LLC y Steven Boyd informan la propiedad beneficiosa de 1.624.000 acciones de Alto Neuroscience (ANRO), que representan el 6,0% del capital social en circulaci贸n, sobre un total de 27.072.129 acciones en circulaci贸n. Armistice Capital, como gestor de inversiones de Armistice Capital Master Fund Ltd., y el Sr. Boyd, como miembro gerente, notifican que poseen poder de voto compartido y poder dispositvo compartido sobre estas acciones y que no tienen poder de voto ni poder dispositvo exclusivo. La presentaci贸n indica que las acciones se mantienen en el curso ordinario del negocio y no con la finalidad de influir en el control. El Master Fund se identifica como el titular directo y conserva el derecho a los ingresos o dividendos de los valores.
Armistice Capital, LLC鞕� 鞀ろ嫲敫� 氤挫澊電� Alto Neuroscience(ANRO)鞚� 氤错喌欤� 1,624,000欤茧ゼ 鞁れ唽鞙犿晿瓿� 鞛堨溂氅�, 鞚措姅 鞝勳泊 鞙犿喌欤检嫕 27,072,129欤� 旮办鞙茧 6.0%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頃╇媹雼�. Armistice Capital鞚� Armistice Capital Master Fund Ltd.鞚� 韴瀽鞖挫毄靷靹�, 氤挫澊電� 甏�毽� 氅る矂搿滌劀 頃措嫻 欤检嫕鞐� 雽�頃� 瓿惦彊 鞚橁舶甓岅臣 瓿惦彊 觳橂秳甓�鞚� 氤挫湢頃橂┌ 雼弲 鞚橁舶甓岇澊雮� 雼弲 觳橂秳甓岇潃 鞐�雼り碃 氤搓碃頃╇媹雼�. 鞝滌稖靹滌棎電� 鞚� 欤检嫕霌れ澊 靷梾鞚� 韱奠儊鞝侅澑 氩旍渼 雮挫棎靹� 氤挫湢霅橁碃 鞛堨溂氅� 歆�氚瓣秾 頄夓偓 氇╈爜鞚� 鞎勲媹霛缄碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. Master Fund臧� 歆侅爲 氤挫湢鞛愲 旮办灛霅橃柎 鞛堨溂氅�, 歃濌秾鞙茧攵�韯� 氚滌儩頃橂姅 靾橃澋 霕愲姅 氚半嫻旮堨潉 氚涭潉 甓岆Μ毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟.
Armistice Capital, LLC et Steven Boyd d茅clarent la propri茅t茅 b茅n茅ficiaire de 1 624 000 actions d'Alto Neuroscience (ANRO), soit 6,0 % des actions ordinaires en circulation sur la base de 27 072 129 actions en circulation. Armistice Capital, en tant que gestionnaire d'investissement d'Armistice Capital Master Fund Ltd., et M. Boyd, en tant que membre g茅rant, d茅clarent disposer d'un pouvoir de vote partag茅 et d'un pouvoir dispositif partag茅 sur ces actions et de aucun pouvoir de vote ni pouvoir dispositif exclusif. Le d茅p么t pr茅cise que les actions sont d茅tenues dans le cours normal des affaires et non dans le but d'influencer le contr么le. Le Master Fund est identifi茅 comme le d茅tenteur direct et conserve le droit aux produits ou dividendes des titres.
Armistice Capital, LLC und Steven Boyd geben den wirtschaftlichen Eigentum an 1.624.000 Aktien von Alto Neuroscience (ANRO) an, was 6,0% des ausstehenden Stammkapitals auf Basis von 27.072.129 ausstehenden Aktien entspricht. Armistice Capital, als Investmentmanager des Armistice Capital Master Fund Ltd., und Herr Boyd, als gesch盲ftsf眉hrendes Mitglied, melden gemeinsames Stimmrecht und gemeinsame Verf眉gungsmacht 眉ber diese Aktien und keine alleinige Stimm- oder Verf眉gungsmacht. In der Meldung hei脽t es, die Aktien w眉rden im normalen Gesch盲ftsverlauf gehalten und nicht mit dem Zweck, die Kontrolle zu beeinflussen. Der Master Fund wird als unmittelbarer Inhaber angegeben und beh盲lt das Recht auf Ertr盲ge oder Dividenden aus den Wertpapieren.
FAQ
How many Alto Neuroscience (ANRO) shares does Armistice Capital report owning?
What percentage of Alto Neuroscience does the reported stake represent?
Does Armistice Capital have sole voting or dispositive power over the shares?
Who is the direct holder of the reported shares?
Does the filing indicate an intent to change or influence control of ANRO?
